Patents by Inventor Karen A. Williams

Karen A. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER
    Publication number: 20130261104
    Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.
    Type: Application
    Filed: May 9, 2013
    Publication date: October 3, 2013
    Applicant: Genentech, Inc.
    Inventors: Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum MacLeod, Karen Williams
  • PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20130252941
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.
    Type: Application
    Filed: May 16, 2013
    Publication date: September 26, 2013
    Applicant: F. Hoffmann-La Roche AG
    Inventors: Toby Blench, Simon Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven Magnuson, Vickie Tsui, Karen Williams, Birong Zhang
  • Diazacarbazoles and methods of use
    Patent number: 8501765
    Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), which are useful as kinase inhibitors, more specifically useful as checkpoint kinase I (chk1) inhibitors, thus useful as cancer therapeutics.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: August 6, 2013
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum MacLeod, Karen Williams
  • Janus kinase inhibitor compounds and methods
    Patent number: 8486950
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: July 16, 2013
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Simon Charles Goodacre, Yingjie Lai, Jun Liang, Steven R. Magnuson, Kirk D. Robarge, Mark S. Stanley, Vickie Hsiao-Wei Tsui, Karen Williams, Birong Zhang, Aihe Zhou
  • Azadecalin glucocorticoid receptor modulators
    Patent number: 8324203
    Abstract: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: December 4, 2012
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul Blaney, Christopher Hurley, Hazel Hunt, David Clark, Karen Williams
  • FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20120225856
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: May 21, 2012
    Publication date: September 6, 2012
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • N-substituted azaindoles and methods of use
    Patent number: 8258152
    Abstract: The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: September 4, 2012
    Assignee: Genentech, Inc.
    Inventors: Hazel Joan Dyke, Stephen Price, Karen Williams
  • AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20120202788
    Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.
    Type: Application
    Filed: September 14, 2011
    Publication date: August 9, 2012
    Inventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven R. Magnuson, Vickie H. Tsui, Karen Williams, Birong Zhang
  • Modified pyrimidine glucocorticoid receptor modulators
    Patent number: 8173664
    Abstract: The present invention provides a class of modified pyrimidine compounds, compositions and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: May 8, 2012
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicolas C. Ray, Karen Williams, Peter H. Crackett, Gwen Hickin, David A. Clark
  • FOAM CONTROL COMPOSITIONS
    Publication number: 20110240914
    Abstract: Disclosed is a method for inhibiting the formation of foam in aqueous systems by adding foam control composition including a polyoxethylene and/or a polyoxypropylene nonionic fatty acid derivative and a quaternary ammonium surfactant.
    Type: Application
    Filed: April 4, 2011
    Publication date: October 6, 2011
    Inventors: John RICHARDSON, Mark Puchovich, Vladimir Djukanovic, Karen Williams
  • 1,7-DIAZACARBAZOLES AND METHODS OF USE
    Publication number: 20110183938
    Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: December 14, 2010
    Publication date: July 28, 2011
    Applicant: Genentech, Inc.
    Inventors: Hazel Joan Dyke, Lewis Gazzard, Karen Williams
  • Fused Ring Azadecalin Glucocorticoid Receptor Modulators
    Publication number: 20110166110
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: March 11, 2011
    Publication date: July 7, 2011
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • DIAZACARBAZOLES AND METHODS OF USE
    Publication number: 20110124654
    Abstract: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: June 10, 2009
    Publication date: May 26, 2011
    Inventors: Huifen Chen, Hazel Joan Dyke, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Joseph Lyssikatos, Calum Macleod, Karen Williams
  • DIAZACARBAZOLES AND METHODS OF USE
    Publication number: 20110118230
    Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: June 10, 2009
    Publication date: May 19, 2011
    Inventors: Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum Macleod, Karen Williams
  • Fused ring azadecalin glucocorticoid receptor modulators
    Patent number: 7928237
    Abstract: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: April 19, 2011
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin D. Clark, Nicholas C. Ray, Paul M. Blaney, Christopher A. Hurley, Karen Williams
  • Aza-benzothiophenyl compounds and methods of use
    Patent number: 7893085
    Abstract: The invention relates to azabenzothiophenyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzothiophenyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: February 22, 2011
    Assignee: Genentech, Inc
    Inventors: Pascal Pierre Savy, Stephen Price, Hazel Joan Dyke, John Gary Montana, Karen Williams, Mark S. Stanley, Liang Bao
  • Aza-indolyl compounds and methods of use
    Patent number: 7855216
    Abstract: The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Karen Williams, Stephen Price, Hazel Joan Dyke, John Gary Montana, Mark S. Stanley, Liang Bao, Wendy Lee
  • JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20100317643
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof
    Type: Application
    Filed: June 10, 2010
    Publication date: December 16, 2010
    Applicant: GENENTECH, INC.
    Inventors: SIMON CHARLES GOODACRE, YINGJIE LAI, JUN LIANG, STEVEN R. MAGNUSON, KIRK D. ROBARGE, MARK S. STANLEY, VICKIE HSIAO-WEI TSUI, KAREN WILLIAMS, BIRONG ZHANG, AIHE ZHOU
  • N-SUBSTITUTED AZAINDOLES AND METHODS OF USE
    Publication number: 20100216768
    Abstract: The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: June 11, 2008
    Publication date: August 26, 2010
    Inventors: Hazel Joan Dyke, Stephen Price, Karen Williams
  • AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20100120759
    Abstract: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Application
    Filed: January 21, 2010
    Publication date: May 13, 2010
    Applicant: Corcept Therapeutics, Inc.
    Inventors: Robin D. CLARK, Nicholas C. RAY, Paul BLANEY, Christopher HURLEY, Hazel HUNT, David CLARK, Karen WILLIAMS